Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
2021
The case of a 45 year old female with chronic migraine undergoing treatment with erenumab 70 mg subcutaneous injection who developed Raynaud’s phenomenon (RP) as a side effect with relevant clinical implications two weeks after the second dose of erenumab injection.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI